Shares of Hims & Hers Health (HIMS) tumbled after the FDA issued a warning against companies marketing unauthorized versions of approved medications. The telehealth provider had recently begun offering a compounded version of semaglutide, the active ingredient in weight loss drugs like Wegovy. This move triggered concerns and a sharp response from competitors.

The FDA's warning, though not directly mentioning Hims & Hers, followed the company's announcement of a lower-cost alternative to Novo Nordisk's Wegovy. Novo Nordisk, the maker of Wegovy, immediately voiced concerns, citing patient safety risks. The Danish drugmaker is known for its proprietary SNAC technology that enables oral absorption of semaglutide, adding to the controversy.

Novo Nordisk saw its shares rise after the FDA announcement. The agency emphasized it cannot verify the quality or safety of unapproved drugs. This raises questions about Hims & Hers' strategy to expand access to weight loss medications at a lower cost, potentially impacting its future. Investors should watch for further regulatory actions.

The situation highlights the ongoing battle within the weight loss drug market as companies compete on price and access to these increasingly popular treatments. With the FDA now involved, the long-term impact on Hims & Hers and its competitors remains to be seen. The market for these drugs is expected to continue growing.